Skip to main content

Advertisement

Table 1 Characteristics and prevalence of comorbid conditions in African American males and females

From: Sex-specific responses to mineralocorticoid receptor antagonism in hypertensive African American males and females

Variable Men (n = 402) Women (n = 1004)
NTN (n = 92) HTN (n = 301) HTN + Spiro (n = 9) NTN (n = 172) HTN (n = 823) HTN + Spiro (n = 9)
Age (year) 58 ± 9 65 ± 9* 63 ± 9 56 ± 10 64 ± 9* 68 ± 9*
BMI (kg/m2) 28 ± 5 29 ± 5* 34 ± 6*# 31 ± 7+ 33 ± 7*+ 33 ± 4
HTN medications 0 1.7 ± 1.1* 2.7 ± 1.3*# 0 1.7 ± 1.1* 1.8 ± 0.8*
HTN duration (year) 0 15 ± 12* 15 ± 11* 0 17 ± 13* 29 ± 11*#+
eGFR (ml/min) 104 ± 17 87 ± 24* 93 ± 14* 96 ± 10+ 87 ± 14* 79 ± 16*
LV mass (g/m2) 75 ± 14 90 ± 22* 90 ± 7* 68 ± 12+ 80 ± 18*+ 73 ± 10+
Total urinary protein (mg) 4 ± 7 16 ± 44* 11 ± 10* 4 ± 6 12 ± 34* 3 ± 3#+
Uncontrolled HTN (%) 0 48* 44* 0 46* 0#+
CHD (%) 2 17* 22* 1 9*+ 11*
MI (%) 0 10* 22* 1 4*+ 11*
Stroke (%) 1 10* 22* 1 5*+ 0
Diabetes (%) 10 30* 11 8 31* 33*
  1. NTN indicates normotension, HTN hypertension, HTN + Spiro hypertension with spironolactone treatment, BMI body mass index, HTN hypertension, eGFR estimate glomerular filtration rate, LV left ventricle, CHD coronary heart disease, MI myocardial infarction. *p < 0.05 vs. NTN, #p < 0.05 vs. HTN, +p < 0.05 vs. men